Celsion’s DNA immunotherapy candidate GEN-1 shows continued positive effect in early-stage ovarian cancer study … – Seeking Alpha
|
Celsion's DNA immunotherapy candidate GEN-1 shows continued positive effect in early-stage ovarian cancer study …
Seeking Alpha Thinly traded nano cap Celsion (CLSN +129.8%) is up on a whopping 36x surge in volume in response to its announcement of final results from a Phase 1b dose-escalating study of DNA immunotherapy GEN-1 in patients with advanced Stage III/IV ovarian … Celsion Announces Final Clinical and Translational Research Data from its OVATION Study at the AACR Special … Celsion Corporation (NASDAQ:CLSN) Stock Traded Higher Than Its 50 Day Moving Average |
